This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Authoring team

 

Type 1

Phenotype

Accounts for 95% of GD cases.

Diverse phenotypes among patients with identical GBA mutations manifests as variations in the overall severity of the disease, as well as in the pattern of organ involvement

Childhood or adult onset varying from asymptomatic to life threatening symptoms.

Symptoms and signs:

  • first appear in adult life and are related to splenomegaly or bone involvement
  • on examination there may be pingueculae (wedge-shaped yellow/orange subconjunctival deposits)
  • yellow-brown pigmentation of the skin, especially that exposed to sunlight

Visceral symptoms

Hepatomegaly (>80% of patients), splenomegaly (>90% of patients), interstitial lung disease and pulmonary hypertension

Hematopoietic symptoms

Anaemia and thrombocytopenia -

  • most commonly - there is pancytopenia or thrombocytopenia secondary to hypersplenism

Orthopaedic symptoms

Bony pain crisis, osteopenia, aseptic necrosis of femoral head, bony lytic lesions, bony infarctions and pathological fractures

Neurologic symptoms

No CNS involvement and no cognitive regression except for an increased risk in Parkinson's disease

Although the disease is progressive in the adult, it is compatible with long life.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.